



AMENDMENTS TO THE CLAIMS


1. (Currently amended) A compound or salt thereof having any one of the following formulas:




Genus I;



Genus II;



Genus III; and



Genus IV;

wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3 , OCF_3 , CONH_2 , CONHR and NHCOR_1 ;

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, substituted polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, polycyclic heterocyclic, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, hydroxyamino, alkoxyamino, carbonyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR', and CONR'R'; and

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.


2. (Previously presented) The compound or salt thereof of Claim 1, wherein said polycyclic aliphatic group is selected from the group consisting of adamantyl, bicycloheptyl, camphoryl, bicyclo[2,2,2]octanyl and norbornyl.

3. (Previously presented) The compound or salt thereof of Claim 1, wherein said heteroaryl and said substituted heteroaryl is selected from the group consisting of pyridines, thiazoles, isothiazoles, oxazoles, pyrimidines, pyrazines, furans, thiophenes, isoxazoles, pyrroles, pyridazines, 1,2,3-triazines, 1,2,4-triazines, 1,3,5-triazines, pyrazoles, imidazoles, indoles, quinolines, iso-quinolines, benzothiophenes, benzofurans, parathiazines, pyrans, chromenes,

pyrrolidines, pyrazolidines, imidazolidines, morpholines, thiomorpholines, and the corresponding heterocyclics.


4. (Cancelled)

5. (Currently amended) The compound or salt thereof of Claim 1, wherein R₁ and R₂ are independently selected from the following:



6. (Currently amended) The compound or salt thereof of Claim 1 selected from the group consisting of compounds S1-S123, T1-T102, U1-U18; and V1-V28 and salts thereof.

7. (Previously presented) A compound or salt thereof represented by one of the following formulas:



Subgenus Ia;

wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF₃, OCF₃, CONH₂, CONHR and NHCOR₁;

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, substituted polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, polycyclic heterocyclic, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;


wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, hydroxyamino, alkoxyamino, carbonyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR', and CONR'R'; and

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said

heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

8. (Currently amended) The compound or salt thereof of Claim 7 selected from the group consisting of compounds S-6, S-96, and S-97 ~~and salts thereof~~.

9. (Previously presented) A compound or salt thereof represented by one of the following formulas:



wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF₃, OCF₃, CONH₂, CONHR and NHCOR₁;

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;


wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, substituted polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, polycyclic heterocyclic, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, hydroxyamino, alkoxyamino, carbonyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR', and CONR'R'; and

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

10. (Currently amended) The compound or salt thereof of Claim 9 selected from the group consisting of compounds T-3, T-83, and T-102 ~~and salts thereof~~.

11. (Previously presented) A compound or salt thereof represented by one of the following formulas:



Subgenus IIb;

wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF₃, OCF₃, CONH₂, CONHR and NHCOR₁;

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, substituted polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, polycyclic heterocyclic, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;


wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said

substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, hydroxyamino, alkoxyamino, carbonyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR', and CONR'R'; and




wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.




12. (Currently amended) The compound or salt thereof of Claim 11 selected from the group consisting of compounds T-88, T-89, T-90, T-91, T-94, and T-96 ~~and salts thereof~~.

13. (Currently amended) A method for treating or preventing an allergic reaction and/or for inhibiting cytokines or leukocytes in a mammal comprising administering an effective amount of at least one of the following compounds compound or salt thereof of Claim 1.



Appl. No. : 10/661,139
Filed : September 12, 2003





wherein R is selected from the group consisting of H, C₁-C₅-alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C₁-C₅-alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉-cycloalkyl, substituted C₃-C₉-cycloalkyl, polycyclic aliphatic groups, substituted polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, polycyclic heterocyclic, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said

~~substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, hydroxyamino, alkoxyamino, carbonyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR', and CONR'R'; and~~

~~wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.~~

14. (Original) The method of Claim 13 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

15. (Original) The method of Claim 14, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.


16. (Currently amended) The method of Claim 14, wherein said at least one additional ingredient is combined with said compound or salt thereof in a pharmaceutically acceptable diluent and co-administered to the mammal.

17. (Currently amended) The method of Claim 13, wherein said compound or salt thereof is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.


18. (Original) The method of Claim 17, wherein said dose is administered in divided doses at regular periodic intervals.

19. (Original) The method of Claim 18, wherein said regular periodic intervals occur daily.


20. (Currently amended) A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one ~~of the following compounds:~~compound or salt thereof of Claim 1.




Genus I;







Genus II;



Genus III;



Genus IV;



wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

~~wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, substituted polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, polycyclic heterocyclic, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~


~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, hydroxyamino, alkoxyamino, carbonyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR', and CONR'R'; and~~

~~wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.~~


21. (Original) The method of Claim 20 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said asthma.

22. (Original) The method of Claim 21, wherein said additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.


23. (Currently amended) A method for inhibiting cellular proliferation in a mammal comprising administering an amount of at least one of the ~~following compounds~~compound or salt thereof of Claim 1.




Genus I;







Genus II;



Genus III;



Genus IV;



wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl and di-alkylamino-alkyl, wherein said C₁-C₅-alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

~~wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, substituted polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, polycyclic heterocyclic, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, hydroxyamino, alkoxyamino, carbonyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR', and CONR'R'; and~~

~~wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.~~

24. (Original) The method of Claim 23 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said cellular proliferation.

25. (Original) The method of Claim 24, wherein said at least one additional ingredient is selected from the group consisting of antifungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.

26. (Original) The method of Claim 24, wherein said at least one additional ingredient is selected from the group consisting of alkylating agent, antimetabolite, DNA cutter, topoisomerase I poison, topoisomerase II poison, DNA binder, and spindle poison.

27. (Currently amended) The method of Claim 24, wherein said at least one additional ingredient is combined with said compound or salt thereof in a pharmaceutically acceptable diluent and co-administered to the mammal.

28. (Currently amended) The method of Claim 23, wherein said compound or salt thereof is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

29. (Original) The method of Claim 28, wherein said dose is administered in divided doses at regular periodic intervals.


30. (Original) The method of Claim 29, wherein said regular periodic intervals occur daily.

31. (Original) The method of Claim 23 further comprising administering at least one other therapy which is effective in ameliorating at least one symptom associated with cellular hyperproliferation.


32. (Original) The method of Claim 31, wherein said therapy is an anti-cancer therapy.

33. (Original) The method of Claim 31, wherein said therapy is selected from the group consisting of radiation, immunotherapy, gene therapy, and surgery.


34. (Previously presented) A method of preparing a compound or salt thereof of Genus I as defined in Claim 1 comprising:



reacting an acyl chloride with said second intermediate, thereby forming a third





reducing said third intermediate, thereby forming a fourth intermediate having




reacting an acyl chloride with the said fourth intermediate, thereby forming a compound of Genus I.


35. (Previously presented) A method of preparing a compound or salt thereof of Genus II as defined in Claim 1 comprising:




reacting said first intermediate with cyanide ion, thereby forming a second




performing hydrolysis on said second intermediate, thereby forming a third



reacting said third intermediate with an alkylamine, thereby forming a fourth





reducing said fourth intermediate; thereby forming a fifth intermediate having




reacting an acyl chloride with said fifth intermediate; thereby forming a compound of Genus II.


36. (Previously presented) A method of preparing a compound or salt thereof of Genus III as defined in Claim 1 comprising:




reacting said first intermediate with a cyanide ion, thereby forming a second




performing hydrolysis on said second intermediate, thereby forming a third



reacting said third intermediate with an alkylamine, thereby forming a fourth





reducing said fourth intermediate; thereby forming a fifth intermediate having




reacting an acyl chloride with said fifth intermediate; thereby forming a compound of Genus III.


37. (Previously presented) A method of preparing a compound or salt thereof of Genus IV as defined in Claim 1 comprising:

reacting a compound having formula:  with a compound


having formula:  , thereby forming a first intermediate having formula:




performing a reductive amination to said first intermediate, thereby forming a



reacting an acyl chloride with said second intermediate, thereby forming a third



reducing said third intermediate, thereby forming a fourth intermediate having



reacting an acyl chloride with said fourth intermediate, thereby forming a compound of Genus IV.

38. (Cancelled)
39. (Cancelled)
40. (Cancelled)
41. (Cancelled)
42. (Previously presented) A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels, inhibiting cellular proliferation, and/or inhibiting cytokines or leukocytes in a mammal comprising one or more of compound or salt thereof of Claim 1.
43. (Previously presented) The pharmaceutical composition of Claim 42, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction, cell proliferation and/or inhibition of cytokines or leukocytes.